Literature DB >> 22794284

Low-grade gliomas: when and how to treat.

Sacit Bulent Omay1, Joseph M Piepmeier, Jonathan P S Knisely.   

Abstract

Low-grade gliomas are uncommon tumors whose optimal management remains to be determined. Although well-designed clinical trials have been mounted to address certain aspects of postoperative radiotherapeutic management, additional studies are required to refine management based on tumor-specific and patient-specific variables. There is mounting evidence that the relative completeness of surgical resection can improve survival, and the molecular and histopathologic characterization of the glioma requires adequate samples for analysis. Current imaging and operative techniques can direct surgical resection, and the same imaging techniques can help monitor patients postoperatively and predict prognosis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22794284     DOI: 10.1016/j.hoc.2012.05.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Older age at the completion of linear growth is associated with an increased risk of adult glioma.

Authors:  Rebecca B Little; L Burt Nabors; Jeffrey J Olson; Zachary J Thompson; Carrie M Rozmeski; Renato V LaRocca; Peter A Forsyth; Reid C Thompson; Robert A Oster; Sajeel A Chowdhary; Kathleen M Egan
Journal:  Cancer Causes Control       Date:  2017-03-04       Impact factor: 2.506

Review 2.  An evidence-based approach to assess the accuracy of intravoxel incoherent motion imaging for the grading of brain tumors.

Authors:  Wen-Fei Li; Chen Niu; Tahir Mehmood Shakir; Tao Chen; Ming Zhang; Zhanqiu Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

3.  Preoperative Contrast-Enhanced MRI in Differentiating Glioblastoma From Low-Grade Gliomas in The Cancer Imaging Archive Database: A Proof-of-Concept Study.

Authors:  Huangqi Zhang; Binhao Zhang; Wenting Pan; Xue Dong; Xin Li; Jinyao Chen; Dongnv Wang; Wenbin Ji
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.